All In Biotech

Drug Trial Radar · NCT06664502

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

A Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Nov 12, 2024

Primary completion

Mar 25, 2026

Study completion Aug 11, 2026

Sponsor

Lead sponsor
EyeBiotech Ltd.Industry
Sponsor type
Industry
First posted
Oct 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.

Conditions

  • Diabetic Macular Edema (DME)
  • Neovascular Age-related Macular Degeneration (NVAMD)
  • BRVO - Branch Retinal Vein Occlusion

Interventions

  • EYE201Drug

    EYE201 solution for intravitreal administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: 12 Weeks

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Scottsdale, Arizona

    Scottsdale, Arizona

  • Modesto, CA

    Modesto, California

  • Mountain View, California

    Mountain View, California

  • Sacramento, CA

    Sacramento, California

  • Sacramento, California

    Sacramento, California

  • Deerfield Beach, FL

    Deerfield Beach, Florida

  • Lemont, IL

    Lemont, Illinois

  • Hagerstown, Maryland

    Hagerstown, Maryland

  • Madison, Mississippi

    Madison, Mississippi

  • Bloomfield, New Jersey

    Bloomfield, New Jersey

  • Asheville, NC

    Asheville, North Carolina

  • Wake Forest, NC

    Wake Forest, North Carolina

  • West Columbia, South Carolina

    West Columbia, South Carolina

  • Germantown, Tennessee

    Germantown, Tennessee

  • Knoxville, TN

    Knoxville, Tennessee

  • Nashville, Tennessee

    Nashville, Tennessee

  • Abilene, Texas

    Abilene, Texas

  • Amarillo, Texas

    Amarillo, Texas

  • Austin, Texas

    Austin, Texas

  • Bellaire, Texas

    Bellaire, Texas

  • Bellaire, TX

    Bellaire, Texas

  • Dallas, Texas

    Dallas, Texas

  • Plano, TX

    Plano, Texas

  • Round Rock, TX

    Round Rock, Texas

  • San Antonio, Texas

    San Antonio, Texas

  • Woodlands, Texas

    The Woodlands, Texas

  • Arecibo, PR

    Arecibo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.